Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib

被引：1
|
作者：
Mok, T. S. K. [1 ]
Liu, G. [2 ]
Nyaw, S. F. [3 ]
Curcio, H. [4 ]
Cortot, A. [5 ]
Kam, T. Y. [6 ]
Descourt, R. [7 ]
Chik, Y. K. [8 ]
Cheema, P. K. [9 ]
Gwinnutt, J. M. [10 ]
Churchill, E. N. [11 ]
Nyborn, J. [12 ]
Curran, E. [13 ]
Yin, Y. [14 ]
Chong, K. [15 ]
Tanaka-Chambers, Y. [16 ]
Kretz, J. [17 ]
Cadranel, J. [18 ,19 ]
机构：
[1] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Princess Margaret Canc Ctr, Ontario Canc Inst, Med Oncol, Toronto, ON, Canada
[3] Tuen Mun Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Ctr Francois Baclesse, Oncol Dept, Caen, France
[5] CHRU Lille, Dept Thorac Oncol, Lille, France
[6] Pamela Youde Nethersole Eastern Hosp Main Block, Dept Clin Oncol, Hong Kong, Peoples R China
[7] CHU Brest, Oncol Dept, Hop Morvan, Brest, France
[8] Queen Elizabeth Hosp QEH, Dept Clin Oncol, Hong Kong, Peoples R China
[9] Univ Toronto, William Osler Hlth Syst, Oncol, Brampton, ON, Canada
[10] IQVIA, Global Epidemiol, Reading, Berks, England
[11] Takeda Pharmaceut USA Inc, Global Med Affairs Oncol, Lexington, MA USA
[12] Takeda Dev Ctr Amer Inc, Global Med Affairs Oncol, Cambridge, MA USA
[13] Takeda Dev Ctr Amer Inc, Global Evidence & Outcome Res, Lexington, MA USA
[14] Takeda Dev Ctr Amer Inc, Observat Res Analyt, Lexington, MA USA
[15] Takeda Dev Ctr Amer Inc, Clin Data Management, Cambridge, MA USA
[16] Takeda Pharmaceut, Stat & Quantitat Sci, Cambridge, MA USA
[17] Takeda Pharmaceut Int AG, Dept Thorac Oncol, Glattpark Opfikon, Zurich, Switzerland
[18] Hop Tenon, AP HP, Pulmonol & Thorac Oncol Dept, Paris, France
[19] Sorbonne Univ Paris, Paris, France
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
585P
引用
收藏
页码：S1698 / S1699
页数：2
相关论文
共 50 条
  • [21] Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)
    Christopoulos, P.
    Prawitz, T.
    Hong, J-L.
    Lin, H. M.
    Hernandez, L.
    Jin, S.
    Tan, M.
    Proskorovsky, I.
    Lin, J.
    Zhang, P.
    Patel, J.
    Ou, S-H. I.
    Thomas, M.
    Stenzinger, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S49 - S49
  • [22] Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
    Byeon, Seonggyu
    Kim, Youjin
    Lim, Sung Won
    Cho, Jang Ho
    Park, Sehoon
    Lee, Jiyun
    Sun, Jong-Mu
    Choi, Yoon-La
    Lee, Se-Hoon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (02): : 623 - 631
  • [23] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
    David, Gil-Sierra Manuel
    del Pilar, Briceno-Casado Maria
    Cristina, Moreno-Ramos
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
  • [24] Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Zhang, Jing
    Li, Wenjie
    BMC PULMONARY MEDICINE, 2025, 25 (01):
  • [25] A real-world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and<sc> EGFR </sc>exon<sc> 20 </sc>insertion mutations
    Suay, Guillermo
    Martin-Martorell, Paloma
    Aparisi, Francisco
    Arnal, Maria
    Guirado, Maria
    Azkarate, Aitor
    Garde-Noguera, Javier
    Cumplido-Buron, Jose David
    Insa, Amelia
    Gonzalez-Munoz, Jose Francisco
    Palanca, Sarai
    Diaz, Maria
    Sanchez-Hernandez, Alfredo
    Juan-Vidal, Oscar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [26] Mechanisms of resistance to mobocertinib in EGFR exon 20 insertion-mutant non-small cell lung cancer (NSCLC)
    Park, S.
    Kim, T. M.
    Kim, S.
    Kim, M.
    Keam, B.
    Kim, D. W.
    Heo, D. S.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S110 - S111
  • [27] Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
    Ou, Sai-Hong Ignatius
    Lin, Huamao M.
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
  • [28] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
    Xu, Shun
    Fu, Zhichao
    CANCER RESEARCH, 2022, 82 (12)
  • [29] EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.
    Chouaid, Christos
    Filleron, Thomas
    Debieuvre, Didier
    Perol, Maurice
    Girard, Nicolas
    Dansin, Eric
    Gervais, Radj
    Cousin, Sophie
    Otto, Josiane
    Schott, Roland
    Planchard, David
    Madroszyk, Anne
    Kaderbhai, Coureche
    Dubray-Longeras, Pascale
    Hiret, Sandrine
    Pichon, Eric
    Clement-Duchene, Christelle Anne
    Martin, Anne-Laure
    Simon, Gaetane
    Quantin, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer
    Leal, Jose Luis
    Alexander, Marliese
    Itchins, Malinda
    Wright, Gavin M.
    Kao, Steven
    Hughes, Brett G. M.
    Pavlakis, Nick
    Clarke, Stephen
    Gill, Anthony J.
    Ainsworth, Hannah
    Solomon, Benjamin
    John, Thomas
    CLINICAL LUNG CANCER, 2021, 22 (06) : E859 - E869
12345